|
|
Resiquimod |
|
Vaxjo ID |
83 |
|
Vaccine Adjuvant Name |
Resiquimod |
|
Adjuvant VO ID |
VO_0001329
|
|
Stage of Development |
Clinical Trial |
|
Function |
Resiquimod, a chemical analog of imiquimod, is a potent modulator of the immune response. Specifically, it was demonstrated that resiquimod activates the innate immune system via TLR-7 through the activation of the MyD88 pathway in antigen presenting cells, including dendritic cells (Otero et al., 2004). |
| References |
Igartua and Pedraz, 2010: Igartua M, Pedraz JL. Topical resiquimod: a promising adjuvant for vaccine development?. Expert review of vaccines. 2010; 9(1); 23-27. [PubMed: 20021302].
Otero et al., 2004: Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine. 2004; 22(13-14); 1782-1790. [PubMed: 15068862].
|
|
